Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 15
Video

The Next Big Thing In Biotech: 2013 Outlook

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.

05:30AM 12/21/12

Video

The Next Big Thing in Biotech: FDA Decisions

By Adam Feuerstein

Senior columnist Adam Feuerstein says three big FDA drug approval decisions are the next big things to watch in biotech.

05:30AM 12/14/12

Video

The Next Big Thing In Biotech: ASH Meeting

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, says the American Society of Hematology meeting is the next big thing to watch in biotech.

06:00AM 12/07/12

Video

The Next Big Thing In Biotech: Ligand, BioMarin & Sangamo

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, says Ligand, BioMarin and Sangamo are the next big things to watch in biotech.

05:30AM 11/30/12

Video

The Next Big Thing in Biotech: Worst CEO Candidates

By Adam Feuerstein

Adam Feuerstein, senior columnist for TheStreet, is assembling candidates for the Worst Biotech CEO of 2012 award.

05:00AM 11/23/12

Video

The Next Big Thing In Biotech: Best CEO Candidates

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, is assembling candidates for the Best Biotech CEO of 2012 award.

05:30AM 11/16/12

Video

The Next Big Thing in Biotech: Dynavax

By Adam Feuerstein

Senior columnist Adam Feuerstein says Dynavax Technologies is the next big thing to watch in biotech.

05:30AM 11/09/12

Video

The Next Big Thing in Biotech

By Adam Feuerstein

Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.

06:00AM 11/02/12

Video

The Next Big Thing in Biotech: Earnings

By Adam Feuerstein

Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.

05:00AM 10/26/12

Video

The Next Big Thing in Biotech: Hepatitis Drugs

By Adam Feuerstein

Senior columnist Adam Feuerstein says hepatitis drugs are the next big thing to watch in biotech.

05:00AM 09/28/12

Page 2 of 15

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 15,307.17 -80.41 -0.52%
NASDAQ 3,463.30 -38.82 -1.11%
S&P 500 1,655.35 -13.81 -0.83%
US 10 Yr 2.026% +0.082

Brokerage Partners

Advertising Partners

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.

Top Rated Stocks Top Rated Funds Top Rated ETFs